

MARKET REPORT



Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017

Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017, provides an overview of the Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline landscape.

Heart failure is also known as congestive heart failure (CHF). CHF is a condition in which the heart is no longer able to pump out enough oxygen-rich blood. Symptoms include cough, fatigue, weakness, faintness, loss of appetite, swollen (enlarged) liver or abdomen, swollen feet and ankles and weight gain. The predisposing factors include high blood pressure, diabetes, sleep apnea, alcohol use and irregular heartbeats. Treatment includes surgery, vasodilator, beta blockers and diuretics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Congestive Heart Failure (Heart Failure) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Congestive Heart Failure (Heart Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 18, 28, 16, 2, 32, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 19 and 8 molecules, respectively.

Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Congestive Heart Failure (Heart Failure) (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Congestive Heart Failure (Heart Failure) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Congestive Heart Failure (Heart Failure) (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Congestive Heart Failure (Heart Failure) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Congestive Heart Failure (Heart Failure) (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Congestive Heart Failure (Heart Failure) (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Additional Details

Publisher : Global Markets Direct

Reference : GMDHC9049IDB

Number of Pages : 364

Report Format : PDF

Publisher Information :



Global Markets Direct
The home of leading edge research and analysis

BioPortfolio
Life Science Healthcare and Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

Table Of Contents for Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017 [Report Updated: 15-03-2017]

- Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Congestive Heart Failure (Heart Failure) - Overview 11
Congestive Heart Failure (Heart Failure) - Therapeutics Development 12
Pipeline Overview 12
Pipeline by Companies 13
Pipeline by Universities/Institutes 19
Products under Development by Companies 22
Products under Development by Universities/Institutes 29
Congestive Heart Failure (Heart Failure) - Therapeutics Assessment 32
Assessment by Target 32
Assessment by Mechanism of Action 37
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Congestive Heart Failure (Heart Failure) - Companies Involved in Therapeutics Development 46
Allosteros Therapeutics Inc 46
Amgen Inc 46
Anexon Inc 47
AnGes MG Inc 47
Arim Pharmaceuticals Inc 48
Arbor Pharmaceuticals LLC 48
Ascelegen Therapeutics Inc 49
AstraZeneca Plc 49
Athersys Inc 50
Bayer AG 50
BEAT BioTherapeutics Corp 51
BioCardia Inc 51
Boehringer Ingelheim GmbH 52
Bristol-Myers Squibb Company 52
Capricor Therapeutics Inc 53
Celixir Ltd 53
Celyad SA 54
Daiichi Sankyo Company Ltd 54
F. Hoffmann-La Roche Ltd 55
FibroGen Inc 55
GlaxoSmithKline Plc 56
Heart Metabolics Ltd 56
Hemostemix Ltd 57
Innopharmax Inc 57
Intrexon Corp 58
Jiangsu Hengrui Medicine Co Ltd 58
Juventas Therapeutics Inc 59
La Jolla Pharmaceutical Company 59
Lead Discovery Center GmbH 60
Lee's Pharmaceutical Holdings Ltd 60
Les Laboratoires Servier SAS 61
Lonestar Heart Inc 61
Madeleine Pharmaceuticals Inc 62
Mast Therapeutics Inc 62
Merck & Co Inc 63
Mesoblast Ltd 63
MorphoSys AG 64
NanoCor Therapeutics Inc 64
Neurocrine Biosciences Inc 65
Novartis AG 65
Nuo Therapeutics Inc 66
Nyken BV 66
Orion Oyj 67
Palatin Technologies Inc 67
PharmaIN Corp 68
PhaseBio Pharmaceuticals Inc 68
Quantum Genomics SA 69
Recardio GmbH 69
RedHill Biopharma Ltd 70
Renova Therapeutics Inc 70
scPharmaceuticals Inc 71
Stealth BioTherapeutics Inc 71
Stemmedica Cell Technologies Inc 72
Target Heart Biotec Srl 72
Theravance Biopharma Inc 73
TiGenix NV 73
Torrent Pharmaceuticals Ltd 74
Trevena Inc 74
U.S. Stem Cell Inc 75
Vicore Pharma AB 75
Zensun (Shanghai) Sci & Tech Co Ltd 76
Congestive Heart Failure (Heart Failure) - Drug Profiles
77(hydralazine + isosorbide dinitrate) XR - Drug Profile
77(sacubitril + valsartan) - Drug Profile
78AAVS-100A1 - Drug Profile
85ACP-01 - Drug Profile
87AdipoCell - Drug Profile
90AE-07 - Drug Profile
93AK-10 - Drug Profile
94aladorian sodium - Drug Profile
95ALD-201 - Drug Profile
97AMG-986 - Drug Profile
99AntimiR-199a - Drug Profile
100Antisense RNAi Gene Therapy to Inhibit ANGPTL2 for Heart Failure - Drug Profile
101ANX-042 - Drug Profile
102ARX-720 - Drug Profile
103AZD-4831 - Drug Profile
104BAY-1753011 - Drug Profile
105BAY-868050 - Drug Profile
106BBR-12 - Drug Profile
107bepermingene perplasmid - Drug Profile
108BMS-986231 - Drug Profile
114C-21 - Drug Profile
116C-Cure - Drug Profile
119CAP-1002 - Drug Profile
125Carfostin - Drug Profile
131carvedilol CR - Drug Profile
132carvedilol phosphate CR - Drug Profile
134Cell Therapy for Heart failure - Drug Profile
135cenderitide - Drug Profile
136cibinetide - Drug Profile
140CLR-325 - Drug Profile
143CTX-101 - Drug Profile
144dapagliflozin propanediol - Drug Profile
146Drug to Inhibit Calpain for Right Heart Failure - Drug Profile
153Drugs to Inhibit miR-425 for Hypertension and Heart Failure - Drug Profile
154ECRA-1 - Drug Profile
155elamipretide - Drug Profile
156empagliflozin - Drug Profile
164enalapril maleate - Drug Profile
173FG-6874 - Drug Profile
174furosemide - Drug Profile
175GDF-11 - Drug Profile
177Gene Therapy for Heart Failure - Drug Profile
178Gene Therapy to Activate Adenylate Cyclase Type 6 for Heart Failure - Drug Profile
179Gene Therapy to Activate GLP-1 for Congestive Heart Failure - Drug Profile
180Gene Therapy to Activate HDAC4 for Heart Failure - Drug Profile
181Gene Therapy to Activate UCn 2 for Congestive Heart Failure - Drug Profile
182Gene Therapy to Inhibit GRK2 for Heart Failure - Drug Profile
183Gene Therapy to Target mAkapbeta for Heart Failure - Drug Profile
184GSK-2798745 - Drug Profile
185istaroxime - Drug Profile
186ITD-1 - Drug Profile
188ivabradine hydrochloride - Drug Profile
189ivabradine hydrochloride SR - Drug Profile
192JVS-100 - Drug Profile
193K-1062 - Drug Profile
198KBP-5074 - Drug Profile
199L-2286 - Drug Profile
201levosimendan - Drug Profile
202milrinone ER - Drug Profile
207Monoclonal Antibody to Activate Sodium Potassium ATPase for Congestive Heart Failure and Status Epilepticus - Drug Profile
208Monoclonal Antibody to Inhibit Periostin 1 for Congestive Heart Failure - Drug Profile
209MP-3167 - Drug Profile
210MPC-150IM - Drug Profile
211MRS-2339 - Drug Profile
216MyoCell - Drug Profile
217MyoCell SDF-1 - Drug Profile
219NBI-69734 - Drug Profile
220neladenoson bialanate - Drug Profile
221Neucardin - Drug Profile
222NM-922 - Drug Profile
225NP-202 - Drug Profile
226NPA-7 - Drug Profile
228NYK-1112 - Drug Profile
229Oligonucleotides to Antagonise Beta 1 Adrenergic Receptor for Pediatric Heart Failure - Drug Profile
230omecantiv mecarbil MR - Drug Profile

231PB-1046 - Drug Profile 239Peptide to Agonize Apelin Receptor for Diabetes and Heart Failure - Drug Profile 241Peptides to Inhibit MyBP-C/Myosin Interaction for Heart Failure - Drug Profile 242perhexiline maleate - Drug Profile 243PF-05285401 - Drug Profile 245PHIN-1138 - Drug Profile 257pirfenidone - Drug Profile 258PL-3994 - Drug Profile 265PL-5028 - Drug Profile 267poloxamer - Drug Profile 268pyroglutaminated serpinin - Drug Profile 270QGC-101 - Drug Profile 271REC-02 - Drug Profile 272Recombinant Protein for Congestive Heart Failure - Drug Profile 273ROMKi-B - Drug Profile 274RT-100 - Drug Profile 275RT-110 - Drug Profile 277RT-300 - Drug Profile 278RT-400 - Drug Profile 279S-38844 - Drug Profile 280serelaxin - Drug Profile 281serpinin - Drug Profile 286SG-1002 - Drug Profile 287Small Molecule to Inhibit BMP for Cardiovascular, CNS, Oncology and Musculoskeletal Disorders - Drug Profile 288Small Molecule to Inhibit CYP11B2 for Heart Failure - Drug Profile 289Small Molecules for Diabetes and Congestive Heart Failure - Drug Profile 290Small Molecules for Diastolic Heart Failure - Drug Profile 291Small Molecules to Activate RXFP1 for Heart Failure and Fibrosis - Drug Profile 292Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile 293Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile 294Small Molecules to Inhibit G betagamma for Heart Failure, Hypertension, Inflammation and Pain - Drug Profile 295Small Molecules to Inhibit GRK2 for Heart Failure - Drug Profile 296Small Molecules to Inhibit PDE4 for Heart Failure - Drug Profile 297Small Molecules to Inhibit PDE5 for Cardiovascular Disease - Drug Profile 298Small molecules to Inhibit Phosphoinositide 3-Kinase Gamma for Heart Failure, Breast Cancer and Chronic Obstructive Pulmonary Disease - Drug Profile 299Small Molecules to Inhibit Porcupine for Oncology, Degenerative Disorders And Congestive Heart Failure - Drug Profile 300Small Molecules to Inhibit RhoGEF12 for Cardiovascular Diseases - Drug Profile 301Small Molecules to Target Beta 2 Adrenergic Receptor and Cannabinoid Receptor for Oncology, Respiratory and Cardiovascular Disorders - Drug Profile 302sodium nitrite - Drug Profile 303SP-20202 - Drug Profile 307Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 308Stem Cell Therapy for CNS Disorders, Rheumatoid Arthritis, Osteoarthritis, Bronchopulmonary Dysplasia and Heart Failure - Drug Profile 314Stem Cell Therapy for Congestive Heart Failure and Kawasaki Disease - Drug Profile 315Stem Cell Therapy for Heart Failure - Drug Profile 316Stem Cell Therapy for Myocardial Infarction and Heart Failure - Drug Profile 317Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - Drug Profile 318Synthetic Peptide to Agonize Beta 2 Adrenergic Receptor for Congestive Heart Failure - Drug Profile 319Synthetic Peptide to Agonize Guanylate Cyclase A for Cardiovascular Disorders - Drug Profile 320TD-0714 - Drug Profile 321TD-1439 - Drug Profile 323TR-4 - Drug Profile 324TRC-4186 - Drug Profile 325TRV-120023 - Drug Profile 327ularitide - Drug Profile 328valsartan CR - Drug Profile 330VCP-746 - Drug Profile 331vericiguat - Drug Profile 332Xcel-hCardP - Drug Profile 334Congestive Heart Failure (Heart Failure) - Dormant Projects 335Congestive Heart Failure (Heart Failure) - Discontinued Products 341Congestive Heart Failure (Heart Failure) - Product Development Milestones 343Featured News & Press Releases 343Appendix 354Methodology 354Coverage 354Secondary Research 354Primary Research 354Expert Panel Validation 354Contact Us 354Disclaimer 355

How to Buy...

Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2017 [Report Updated: 15-0-2017]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/47500>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$2000** | Single User Price
- \$4000** | Site License Price
- \$6000** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.